Cited by 2,323COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchRespiratory viral infections research

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Open access

Hammond, Jennifer, Leister-Tebbe, Heidi, Gardner, Annie, Abreu, Paula, Bao, Weihang, Wisemandle, Wayne, Baniecki, MaryLynn, Hendrick, Victoria M., Damle, Bharat, Simón-Campos, Abraham, Pypstra, Rienk, Rusnak, James M.·2022·New England Journal of Medicine

DOI 10.1056/nejmoa2118542PMC PMC8908851

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUNDNirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (M pro ) inhibitor with potent pan-human-coronavirus activity in vitro. METHODSWe conducted a phase 2-3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days.Covid-19-related hospitalization or death from any cause through day 28, viral load, and safety were evaluated. RESULTSA total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir group) and 1126 received placebo (placebo group).In the planned interim analysis of patients treated within 3 days after symptom onset (modified intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19-related hospitalization or death by day 28 was lower in the nirmatrelvir group than in the placebo group by 6.32 percentage points (95% confidence interval [CI], -9.04 to -3.59; P<0.001; relative risk reduction, 89.1%); the incidence was 0.77% (3 of 389 patients) in the nirmatrelvir group, with 0 deaths, as compared with 7.01% (27 of 385 patients) in the placebo group, with 7 deaths.Efficacy was maintained in the final analysis involving the 1379 patients in the modified intention-to-treat population, with a difference of -5.81 percentage points (95% CI, -7.78 to -3.84; P<0.001; relative risk reduction, 88.9%).All 13 deaths occurred in the placebo group.The viral load was lower with nirmatrelvir plus ritonavir than with placebo at day 5 of treatment, with an adjusted mean difference of -0.868 log 10 copies per milliliter when treatment was initiated within 3 days after the onset of symptoms.The incidence of adverse events that emerged during the treatment period was similar in the two groups (any adverse event, 22.6% with nirmatrelvir plus ritonavir vs. 23.9% with placebo; serious adverse events, 1.6% vs. 6.6%; and adverse events leading to discontinuation of the drugs or placebo, 2.1% vs. 4.2%).Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with nirmatrelvir plus ritonavir than with placebo. CONCLUSIONSTreatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns.(Supported by Pfizer; ClinicalTrials.govnumber, NCT04960202.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2118542

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.010 · Cited by 11,449
Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants.
(2016) · The Lancet · doi:10.1016/s0140-6736(16)30054-x · Cited by 5,212
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis
Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J., Li, Q., Jiang, C., Zhou, Y., Liu, S., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.04.021 · Cited by 2,074
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science · doi:10.1126/science.abl4784 · Cited by 2,033

Show all 21 references

Sorted by citations

Items 301–400 of 1,002

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains
Bouzidi, H. S., Driouich, J., Klitting, R., Bernadin, O., Piorkowski, G., Amaral, R., Fraisse, L., Mowbray, C. E., Scandale, I., Escudié, F., et al. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105814 · Cited by 28
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies
Chaer, F. E., Auletta, J. J., & Chemaly, R. F. (2022) · Blood · doi:10.1182/blood.2022016089 · Cited by 27
Paxlovid-Tacrolimus Drug–Drug Interaction in a 23-Year-Old Female Kidney Transplant Patient with COVID-19
Yanay, N. B., Bogner, I., Saker, K., & Tannous, E. E. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01180-4 · Cited by 27
Race, Ethnicity, and Health Disparities in US Children With COVID-19: A Review of the Evidence and Recommendations for the Future
Miguel, C. P. V., Dasgupta-Tsinikas, S., Lamb, G. S., Olarte, L., & Santos, R. P. (2022) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piac099 · Cited by 28
Paxlovid (Nirmatrelvir and Ritonavir) Use in Pregnant and Lactating Woman: Current Evidence and Practice Guidelines—A Scoping Review
Chourasia, P. K., Maringanti, B. S., Edwards‐Fligner, M., Gangu, K., Bobba, A., Sheikh, A. B., & Shekhar, R. (2023) · Vaccines · doi:10.3390/vaccines11010107 · Cited by 27
The possible therapeutic role of curcumin and quercetin in the early-stage of COVID-19—Results from a pragmatic randomized clinical trial
Ujjan, I. D., Khan, S., Nigar, R., Ahmed, H., Ahmad, S., & Khan, A. P. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1023997 · Cited by 29
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients
Bruel, T., Vrignaud, L.-L., Porrot, F., Staropoli, I., Planas, D., Guivel‐Benhassine, F., Puech, J., Prot, M., Munier, S., Bolland, W., et al. (2023) · Med · doi:10.1016/j.medj.2023.07.007 · Cited by 27
Wonder of wonders, miracle of miracles: the unprecedented speed of COVID-19 science
Saag, M. S. (2022) · Physiological Reviews · doi:10.1152/physrev.00010.2022 · Cited by 28
Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial
Lacombe, K., Hueso, T., Porcher, R., MEKINIAN, A., Chiarabini, T., Georgin‐Lavialle, S., Ader, F., Saison, J., Martin‐Blondel, G., Castro, N. D., et al. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000427 · Cited by 28
Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial
Lu, H., Zhang, G., Mao, J., Chen, X., Zhan, Y., Lin, L., Zhang, T., Tang, Y., Lin, F., Zhu, F., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102582 · Cited by 26
Stereoconvergent, photocatalytic cyclopropanation reactions of β-substituted styrenes with ethyl diazoacetate
Langletz, T., Empel, C., Jana, S., & Koenigs, R. M. (2022) · Tetrahedron Chem · doi:10.1016/j.tchem.2022.100024 · Cited by 26
Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
Li, M., Zhang, Q., Liu, X., Wang, H., & Liu, W. (2022) · Pharmaceuticals · doi:10.3390/ph15121455 · Cited by 26
The impact of SARS-CoV-2 3CL protease mutations on nirmatrelvir inhibitory efficiency. Computational insights into potential resistance mechanisms
Ramos‐Guzmán, C. A., Andjelkovic, M., Zinovjev, K., Ruiz‐Pernía, J. J., & Tuñón, I. (2023) · Chemical Science · doi:10.1039/d2sc06584c · Cited by 26
Plant flavonoid inhibition of SARS-CoV-2 main protease and viral replication
Lin, L., Chen, D. W., Scartelli, C., Xie, H., Merrill‐Skoloff, G., Yang, M., Sun, L., Saeed, M., & Flaumenhaft, R. C. (2023) · iScience · doi:10.1016/j.isci.2023.107602 · Cited by 26
Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial
Wang, B., Li, H., Cai, M.-M., Lin, Z.-X., Ou, X.-F., Wu, S.-H., Cai, R.-H., Wei, Y.-N., Yang, F., Zhu, Y.-M., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102189 · Cited by 26
Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19
Boulware, D. R., Lindsell, C. J., Stewart, T. G., Hernandez, A. F., Collins, S. P., McCarthy, M. W., Jayaweera, D. T., Gentile, N., Castro, M., Sulkowski, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2209421 · Cited by 26
Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review
Xiao, Y.-Q., Long, J., Zhang, S., Zhu, Y., & Gu, S. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107380 · Cited by 26
Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-RitonavirPreprint
Dai, E. Y., Lee, K. A., Nathanson, A. B., Leonelli, A. T., Petros, B. A., Brock-Fisher, T., Dobbins, S. T., MacInnis, B. L., Capone, A., Littlehale, N., et al. (2022) · medRxiv · doi:10.1101/2022.08.04.22278378 · Cited by 26
Ritonavir’s Evolving Role: A Journey from Antiretroviral Therapy to Broader Medical Applications
Pereira, M., & Vale, N. (2024) · Current Oncology · doi:10.3390/curroncol31100450 · Cited by 25
Smart therapies against global pandemics: A potential of short peptides
Apostolopoulos, V., Bojarska, J., Feehan, J., Matsoukas, J., & Wolf, W. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.914467 · Cited by 25
AI-Driven Discovery of SARS-CoV-2 Main Protease Fragment-like Inhibitors with Antiviral Activity In Vitro
Saramago, L., Santana, M. V., Gomes, B. F., Dantas, R. F., Senger, M. R., Borges, P. H. O., Ferreira, V. N. D. S., Rosa, A. D. S., Tucci, A. R., Miranda, M. D., et al. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00409 · Cited by 25
DeepCoVDR: deep transfer learning with graph transformer and cross-attention for predicting COVID-19 drug response
Huang, Z., Zhang, P., & Deng, L. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad244 · Cited by 26
An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo
Tsuji, M., Nair, M. S., Masuda, K., Castagna, C., Chong, Z., Darling, T. L., Seehra, K., Hwang, Y., Ribeiro, Á. L., Ferreira, G. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39738-1 · Cited by 25
Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)
Jittamala, P., Schilling, W. H., Watson, J. A., Luvira, V., Siripoon, T., Ngamprasertchai, T., Almeida, P. J., Ekkapongpisit, M., Cruz, C. V., Callery, J. J., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad275 · Cited by 25
Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group
Ren, P., Li, H., Nie, T., Jian, X., Yu, C., Li, J., Su, H., Zhang, X., Li, S., Yang, X., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00818 · Cited by 25
Exploring the structural and molecular interaction landscape of nirmatrelvir and Mpro complex: The study might assist in designing more potent antivirals targeting SARS-CoV-2 and other viruses
Chakraborty, C., Bhattacharya, M., Alshammari, A., Alharbi, M., Albekairi, T. H., & Zheng, C. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.09.020 · Cited by 25
Recent advances in anti-inflammatory active components and action mechanisms of natural medicines
Wu, Z., Zhang, T., Ma, X., Guo, S., Zhou, Q., Zahoor, A., & Deng, G. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01369-9 · Cited by 25
Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States
Carlson, J. J., FOOS, V., Kasle, A., Mugwagwa, T., Draica, F., Wiemken, T. L., Nguyen, J. L., Cha-Silva, A. S., Migliaccio–Walle, K., & Dzingina, M. (2023) · Value in Health · doi:10.1016/j.jval.2023.11.003 · Cited by 24
Extended nirmatrelvir–ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial
Weinstein, E. A., Paredes, R., Gardner, A., Almas, M., Baniecki, M. L., Guan, S., Tudone, E., Antonucci, S., Gregg, K., García‐Vidal, C., et al. (2025) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(25)00221-x · Cited by 24
Self-citation
Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19
Girardin, F., Manuel, O., Marzolini, C., & Buclin, T. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.03.030 · Cited by 24
Mechanistic Models of COVID-19: Insights into Disease Progression, Vaccines, and Therapeutics
Desikan, R., Padmanabhan, P., Kierzek, A. M., & van der Graaf, P. H. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106606 · Cited by 24
From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?
Pavan, M., Bassani, D., Sturlese, M., & Moro, S. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2081847 · Cited by 24
Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendations
Passamonti, F., Nicastri, E., Rocco, A. D., Guarini, A., Ibatici, A., Luminari, S., Mikulska, M., & Visco, C. (2022) · Hematological Oncology · doi:10.1002/hon.3086 · Cited by 26
A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19
Haddad, F., Dokmak, G., & Karaman, R. (2022) · Life · doi:10.3390/life12111758 · Cited by 25
Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404
Fàbrega-Ferrer, M., Herrera-Morandé, A., Muriel-Goñi, S., Pérez-Saavedra, J., Bueno, P., Castro, V. A., Garaigorta, U., Gastaminza, P., & Coll, M. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105458 · Cited by 24
Anti-inflammatory effects of medications used for viral infection-induced respiratory diseases
Yamaya, M., Kikuchi, A., Sugawara, M., & Nishimura, H. (2022) · Respiratory Investigation · doi:10.1016/j.resinv.2022.11.002 · Cited by 24
Impact of Early SARS-CoV-2 Antiviral Therapy on Disease Progression
VITO, A. D., Colpani, A., Saderi, L., Puci, M. V., Zauli, B., Fiore, V., Fois, M., Meloni, M. C., Bitti, A., Castri, C. D., et al. (2022) · Viruses · doi:10.3390/v15010071 · Cited by 24
Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses
Brier, L., Hassan, H., Hanoulle, X., Landry, V., Moschidi, D., Desmarets, L. M. B., Rouillé, Y., Dumont, J., Herlédan, A., Warenghem, S., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115186 · Cited by 24
COVID-19 therapy and vaccination: a clinical narrative review
Chinta, S. R., Guerra, M. A. R., Shaban, M., Pandey, N., Jaquez-Duran, M., & Vittorio, T. J. (2023) · Drugs in Context · doi:10.7573/dic.2022-7-2 · Cited by 25
Development of a Manufacturing Process toward the Convergent Synthesis of the COVID-19 Antiviral Ensitrelvir
Kawajiri, T., Kijima, A., Iimuro, A., Ohashi, E., Yamakawa, K., Agura, K., Masuda, K., Kouki, K., Kasamatsu, K., Yanagisawa, S., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.2c01203 · Cited by 24
Persistent SARS-CoV-2 PCR Positivity Despite Anti-viral Treatment in Immunodeficient Patients
Chan, M. M. H., Linn, M. M. N., O’Hagan, T., Guerra‐Assunção, J. A., Lackenby, A., Workman, S., Dacre, A., Burns, S. O., Breuer, J., Hart, J., et al. (2023) · Journal of Clinical Immunology · doi:10.1007/s10875-023-01504-9 · Cited by 26
RETRACTED AND REPLACED: Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019–Associated Hospitalization Prevention: A Population-based Cohort Study in the Province of Quebec, Canada
Kaboré, J., Laffont, B., Diop, M., Tardif, M. R., Turgeon, A. F., Dumaresq, J., Luong, M., Cauchon, M., Chapdelaine, H., Claveau, D., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad287 · Cited by 24
Retracted
Long COVID and possible preventive options
Sebők, S., & Gyires, K. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01204-1 · Cited by 24
Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants
Cox, D. S., Rehman, M., Khan, T. M., Ginman, K., Salageanu, J., LaBadie, R. R., Wan, K., & Damle, B. D. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15835 · Cited by 24
Self-citation
Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18–50 Years
Faust, J. S., Kumar, A., Shah, J., Khadke, S., Dani, S. S., Ganatra, S., & Sax, P. E. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad400 · Cited by 24
Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2
Bowden-Reid, E., Ledger, S., Zhang, Y., Giallonardo, F. D., Aggarwal, A., Stella, A. O., Akerman, A., Milogiannakis, V., Walker, G. J., Rawlinson, W. D., et al. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105677 · Cited by 24
Effectiveness of community-based oral antiviral treatments against severe COVID-19 outcomes in people 70 years and over in Victoria, Australia, 2022: an observational study
Heer, C. V., Majumdar, S., Parta, I., Martinie, M. F. R. C., Dawson, R., West, D., Hewett, L., Lister, D., Sutton, B. A., O'Brien, D. P., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100917 · Cited by 24
Public Health Impact of Paxlovid as Treatment for COVID-19, United States
Bai, Y., Du, Z., Wang, L., Lau, E. H. Y., Fung, I. C., Holme, P., Cowling, B. J., Galvani, A. P., Krug, R. M., & Ancel, L. W. (2024) · Emerging infectious diseases · doi:10.3201/eid3002.230835 · Cited by 24
Clinical Risk and Outpatient Therapy Utilization for COVID-19 in the Medicare Population
Wilcock, A. D., Kissler, S. M., Mehrotra, A., McGarry, B. E., Sommers, B. D., Grabowski, D. C., Grad, Y. H., & Barnett, M. L. (2024) · JAMA Health Forum · doi:10.1001/jamahealthforum.2023.5044 · Cited by 24
Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19
Takazono, T., Fujita, S., Komeda, T., Miyazawa, S., Yoshida, Y., Kitanishi, Y., Kinoshita, M., Kojima, S., Shen, H., Uehara, T., et al. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01010-4 · Cited by 24
A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects
Bai, Y., Seng, D., Xu, Y. C., Zhang, Y., Zhou, W., Jia, Y.-Y., Song, J. Z., He, Z., Liu, H., & Yuan, S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116706 · Cited by 24
Structural review of SARS-CoV-2 antiviral targets
Cui, W., Duan, Y., Gao, Y., Wang, W., & Yang, H. (2024) · Structure · doi:10.1016/j.str.2024.08.005 · Cited by 24
Toward the Design of Allosteric Effectors: Gaining Comprehensive Control of Drug Properties and Actions
Tee, W.-V., Lim, S. J. M., & Berezovsky, I. N. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01043 · Cited by 23
Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic
Suzuki, Y., Shibata, Y., Minemura, H., Nikaido, T., Tanino, Y., Fukuhara, A., Kanno, R., Saito, H., Suzuki, S., Inokoshi, Y., et al. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00949-3 · Cited by 24
Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19
Graziani, L., Gori, L., Manciulli, T., Basile, G., Campolmi, I., Borchi, B., di Dio, M., Mattei, M., Ciurleo, G., Ciliberti, M., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac433 · Cited by 24
Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial
Kaizer, A. M., Shapiro, N. I., Wild, J. L., Brown, S. M., Cwik, B. J., Hart, K. W., Jones, A. E., Pulia, M. S., Self, W. H., Smith, C. B., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.12.028 · Cited by 24
MEK inhibitors as novel host-targeted antivirals with a dual-benefit mode of action against hyperinflammatory respiratory viral diseases
Ludwig, S., Pleschka, S., & Planz, O. (2023) · Current Opinion in Virology · doi:10.1016/j.coviro.2023.101304 · Cited by 23
Evaluation of Broad Anti-Coronavirus Activity of Autophagy-Related Compounds Using Human Airway Organoids
Hashimoto, R., Tamura, T., Watanabe, Y., Sakamoto, A., Yasuhara, N., Ito, H., Nakano, M., Fuse, H., Ohta, A., Noda, T., et al. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00114 · Cited by 23
Compounds from myrtle flowers as antibacterial agents and SARS-CoV-2 inhibitors: In-vitro and molecular docking studies
Barhouchi, B., Menacer, R., Bouchkioua, S., Mansour, A. M., & Belattar, N. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.104939 · Cited by 23
Effective prognostic and clinical risk stratification in COVID‐19 using multimodality biomarkers
Liu, A., Hammond, R., Donnelly, P., Kaski, J. C., & Coates, A. R. M. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13646 · Cited by 24
Multi-omics for COVID-19: driving development of therapeutics and vaccines
Guo, M., Xiong, M., Peng, J., Guan, T., Su, H., Huang, Y., Yang, C., Li, Y., Boraschi, D., Pillaiyar, T., et al. (2023) · National Science Review · doi:10.1093/nsr/nwad161 · Cited by 24
Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease
Ngo, C., Fried, W., Aliyari, S. R., Feng, J. J., Qin, C., Zhang, S., Yang, H., Shanaa, J., Feng, P., Cheng, G., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00810 · Cited by 23
Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: Systematic review and meta-analyses of observational studies
Souza, K. M., Carrasco, G., Rojas-Cortés, R., Barbosa, M. M., Bambirra, E. H. F., Castro, J. L., & Álvares-Teodoro, J. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284006 · Cited by 23
Real-World Effectiveness of Nirmatrelvir/Ritonavir in Preventing Hospitalization Among Patients With COVID-19 at High Risk for Severe Disease in the United States: A Nationwide Population-Based Cohort StudyPreprint
Zhou, X., Kelly, S. P., Liang, C., Li, L., Shen, R., Leister-Tebbe, H. K., Terra, S. G., Gaffney, M., & Russo, L. (2022) · medRxiv · doi:10.1101/2022.09.13.22279908 · Cited by 24
Self-citation
Structural and virologic mechanism of the emergence of resistance to M pro inhibitors in SARS-CoV-2
Hattori, S.-I., Bulut, H., Hayashi, H., Kishimoto, N., Takamune, N., Hasegawa, K., Furusawa, Y., Yamayoshi, S., Murayama, K., Tamamura, H., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2404175121 · Cited by 22
COVID-19 clinical presentation, management, and epidemiology: a concise compendium
Maison, D. P., Tasissa, H., Deitchman, A. N., Peluso, M. J., Deng, Y., Miller, F. D., Henrich, T. J., & Gerschenson, M. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1498445 · Cited by 26
Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial
Luetkemeyer, A. F., Chew, K. W., Lacey, S., Hughes, M. D., Harrison, L. J., Daar, E. S., Eron, J. J., Fletcher, C. V., Greninger, A. L., Hessinger, D., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf029 · Cited by 22
The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review
Kamal, L., Ramadan, A., Farraj, S. A., Bahig, L., & Ezzat, S. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.03.002 · Cited by 22
Coronaviral Infection and Interferon Response: The Virus-Host Arms Race and COVID-19
Liu, Q., Chi, S., Dmytruk, K. V., Dmytruk, O. V., & Tan, S. (2022) · Viruses · doi:10.3390/v14071349 · Cited by 24
Short-term Pregnancy Outcomes After Nirmatrelvir–Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
Loza, A., Farias, R., Gavin, N., Wagner, R., Hammer, E., & Shields, A. D. (2022) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004900 · Cited by 22
Modeling Kaempferol as a Potential Pharmacological Agent for COVID-19/PF Co-Occurrence Based on Bioinformatics and System Pharmacological Tools
Jiang, Y., Xie, Y., Peng, C.-W., Yao, K., Xue-ying, L., Zhan, S., Zhuang, H., Huang, H.-T., Liu, X.-H., Huang, X., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.865097 · Cited by 22
Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial
Peto, L., Horby, P., & Landray, M. (2022) · Advances in Biological Regulation · doi:10.1016/j.jbior.2022.100901 · Cited by 22
COVID-19 and HSCT (Hematopoietic stem cell transplant)
Strasfeld, L. M. (2022) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2022.101399 · Cited by 22
Risk factors for severe infection and mortality In patients with COVID ‐19 in patients with multiple myeloma and AL amyloidosis
Ho, M., Zanwar, S., Buadi, F. K., Ailawadhi, S., Larsen, J. T., Bergsagel, P. L., Binder, M., Chanan-Khan, A. A., Dingli, D., Dispenzieri, A. A., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26762 · Cited by 22
Multicenter, randomized controlled trial of traditional Japanese medicine, kakkonto with shosaikotokakikyosekko, for mild and moderate coronavirus disease patients
Takayama, S., Namiki, T., Arita, R., Ono, R., Kikuchi, A., Ohsawa, M., Saito, N., Suzuki, S., Nakae, H., Kobayashi, S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1008946 · Cited by 22
Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents
Gentry, C. A., Nguyen, P. N., Thind, S. K., Kurdgelashvili, G., & Williams, R. J. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.01.018 · Cited by 22
Postmarketing Reporting of Paxlovid‐Related Dysgeusia: A Real‐World Pharmacovigilance Study
Cvancara, D. J., Baertsch, H., Lehmann, A. E., Humphreys, I. M., Farrell, N. F., Marshall, T. B., Bhatt, N. K., Abuzeid, W. M., & Jafari, A. (2023) · Otolaryngology · doi:10.1002/ohn.278 · Cited by 22
Therapeutic potential of salicylamide derivatives for combating viral infections
Xu, J., Xue, Y., Bolinger, A. A., Li, J., Zhou, M., Chen, H., Li, H., & Zhou, J. (2023) · Medicinal Research Reviews · doi:10.1002/med.21940 · Cited by 23
Green adherent degradation kinetics study of Nirmatrelvir, an oral anti-COVID-19: characterization of degradation products using LC–MS with insilico toxicity profile
Aboras, S. I., & Maher, H. M. (2023) · BMC Chemistry · doi:10.1186/s13065-023-00928-z · Cited by 22
Nirmatrelvir treatment of SARS‐CoV‐2‐infected mice blunts antiviral adaptive immune responses
Fumagalli, V., Lucia, P. D., Ravà, M., Marotta, D., Bono, E. B., Grassi, S., Donnici, L., Cannalire, R., Stefanelli, I., Ferraro, A., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202317580 · Cited by 22
A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventions
Rao, R. P., Musante, C. J., & Allen, R. (2023) · npj Systems Biology and Applications · doi:10.1038/s41540-023-00269-6 · Cited by 23
Integrative Approach to Dissect the Drug Resistance Mechanism of the H172Y Mutation of SARS-CoV-2 Main Protease
Clayton, J., de Oliveira, V. M., Ibrahim, M. F., Sun, X., Mahinthichaichan, P., Shen, M., Hilgenfeld, R., & Shen, J. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00344 · Cited by 23
High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients
Huygens, S., Gharbharan, A., Serroukh, Y. I. M., Snoek, B., Franken, B., Munnink, B. B. O., van Hagen, P. M., Bogers, S., GeurtsvanKessel, C. H., & Rijnders, B. J. A. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad144 · Cited by 22
Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
Zhao, Q., Zheng, B., Han, B., Feng, P., Xia, Z., Jiang, H., Yin, Y., Zhu, J., Fei, C., Xiang, J., et al. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-023-00845-7 · Cited by 22
Tailoring two white chromatographic platforms for simultaneous estimation of ritonavir-boosted nirmatrelvir in their novel pills: degradation, validation, and environmental impact studies
Elbordiny, H. S., Alzoman, N. Z., Maher, H. M., & Aboras, S. I. (2023) · RSC Advances · doi:10.1039/d3ra04186g · Cited by 22
Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
Gammeltoft, K. A., Zhou, Y., Ryberg, L. A., Pham, L. V., Binderup, A., Hernandez, C. R. D., Offersgaard, A., Fahnøe, U., Peters, G. H. J., Ramírez, S., et al. (2023) · Viruses · doi:10.3390/v15091970 · Cited by 22
Approach to COVID-19 in older adults and indications for improving the outcomes
Tana, C., Moffa, L., Falasca, K., Vecchiet, J., Tana, M., Mantini, C., Ricci, F., Ticinesi, A., Meschi, T., Cipollone, F., et al. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2265298 · Cited by 23
USP2 inhibition prevents infection with ACE2-dependent coronaviruses in vitro and is protective against SARS-CoV-2 in mice
Dang, F., Bai, L., Dong, J., Hu, X., Wang, J., Paulo, J. A., Xiong, Y., Liang, X., Sun, Y., Chen, Y., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh7668 · Cited by 23
Ensitrelvir in patients with SARS-CoV-2: A retrospective chart review
Yamato, M., Kinoshita, M., Miyazawa, S., Seki, M., Mizuno, T., & Sonoyama, T. (2024) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2024.02.015 · Cited by 22
Real-world effectiveness of nirmatrelvir-ritonavir and molnupiravir in non-hospitalized adults with COVID-19: a population-based, retrospective cohort study
Jorda, A., Ensle, D., Eser, H., Glötzl, F., Riedl, B., Széll, M., Valipour, A., Zoufaly, A., Wenisch, C., Haider, D., et al. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.10.026 · Cited by 21
Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid™
Sathish, J. G., Bhatt, S., DaSilva, J. K., Flynn, D. A., Jenkinson, S. G., Kalgutkar, A. S. S., Liu, M., Manickam, B., Pinkstaff, J. K., Reagan, W. J., et al. (2022) · International Journal of Toxicology · doi:10.1177/10915818221095489 · Cited by 21
COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature
Alshanqeeti, S., & Bhargava, A. (2022) · Cureus · doi:10.7759/cureus.26239 · Cited by 21
Traditional Chinese Medicine JingYinGuBiao Formula Therapy Improves the Negative Conversion Rate of SARS-CoV2 in Patients with Mild COVID-19
Chen, B., Geng, P., Shen, J., Liangpunsakul, S., Lyu, H., Zhang, J., Yang, Y., Zhang, L., Xu, Y., Dong, C., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.76699 · Cited by 21
Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis
Savinkina, A. A., Paltiel, A. D., Ross, J. S., & Gonsalves, G. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac637 · Cited by 21
Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)
Schilling, W. H., Jittamala, P., Watson, J. A., Ekkapongpisit, M., Siripoon, T., Ngamprasertchai, T., Luvira, V., Pongwilai, S., Cruz, C. V., Callery, J. J., et al. (2023) · eLife · doi:10.7554/elife.83201 · Cited by 21
Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab
Franceschini, E., Pellegrino, M., Todisco, V., Dolci, G., Bettelli, F., Meschiari, M., Bedini, A., Serpini, G. F., Grottola, A., Guaraldi, G., et al. (2023) · Infection · doi:10.1007/s15010-023-02039-2 · Cited by 21
Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes
Ma, B. H.-M., Yip, T. C., Lui, G. C.-Y., Lai, M. S., Hui, E., Wong, V. W., Tse, Y., Chan, H. L., Hui, D. S. C., Kwok, T. C. Y., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.10887 · Cited by 21
Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID‐19
Wu, J., Liu, M., Liu, T., Chuang, M., Hsu, W., Huang, P., Tsai, Y., Kuo, C., Yeh, C., & Lai, C. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28866 · Cited by 21
Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
Siripongboonsitti, T., Ungtrakul, T., Tawinprai, K., Auewarakul, C. U., Chartisathian, W., Jansala, T., Julsawad, R., Soonklang, K., Mahanonda, N., & Mahidol, C. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155018 · Cited by 21
COVID-19
Marks, K., & Gulick, R. M. (2023) · Annals of Internal Medicine · doi:10.7326/aitc202310170 · Cited by 21

Authors: Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., Pypstra, R., & Rusnak, J. M.
Affiliations: Pfizer (United States) (US)
From Global Product Development, Pfizer, Collegeville, PA (J.H., H.L.-T.); Global Product Development (A.G.) and Early Clinical Development (M.L.B.), Pfizer, Cambridge, MA; Global Product Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global Product Development, Pfizer, Tampa, FL (J.M.R.).
Corresponding author: Hammond, Jennifer
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2022-04-14
Volume: 386
Issue: 15
Pages: 1397-1408
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2118542
PMC: PMC8908851
OpenAlex: W4212904481
Cited by: 2,323
References: 21
Citations by year: 2026: 186 · 2025: 319 · 2024: 517 · 2023: 769 · 2022: 525
FWCI: 261.43
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Pfizer
Topics: Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Keywords: nirmatrelvir, COVID-19 pandemic, SARS-CoV-2, Mpro inhibitors, ritonavir, oral antiviral therapy, high-risk adults, non-hospitalized patients, viral load, unvaccinated patients, early treatment, SARS-CoV-2 variants, Omicron variant
MeSH terms: Viral Protease Inhibitors, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Administration, Oral, Adult, Antiviral Agents, Double-Blind Method, Drug Combinations, Hospitalization, Humans, Lactams, Leucine, Nitriles, Proline, Vaccination, Treatment Outcome, Disease Progression, Ritonavir, Viral Load

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks